High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
暂无分享,去创建一个
C. Rinaldo | Xiao-li Huang | M. Cottrill | A. Logar | G. Mazzara | D. Panicali | M. Ding | Z. Fan | P. Gupta | L. Beltz | J. Liebmann | X. Huang | Martin Cottrill | Xiao-li Huang | Xiao-li Huang
[1] L. Kingsley,et al. Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay , 1995, Journal of clinical microbiology.
[2] J. Mellors,et al. Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.
[3] J. Margolick,et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[4] C. Rinaldo,et al. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. , 1995, AIDS research and human retroviruses.
[5] J. Margolick,et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.
[6] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[7] E. Vicenzi,et al. Regulation of HIV expression by viral genes and cytokines , 1994, Journal of leukocyte biology.
[8] J. Levy,et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein , 1994, The Journal of experimental medicine.
[9] R. Welsh,et al. Specificity and editing by apoptosis of virus-induced cytotoxic T lymphocytes. , 1994, Current opinion in immunology.
[10] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[11] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[12] H. Sheppard,et al. Circulating HIV-1-infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. , 1994, Journal of acquired immune deficiency syndromes.
[13] S. Chevret,et al. Provirus copy number to predict disease progression in asymptomatic human immunodeficiency virus type 1 infection. , 1994, The Journal of infectious diseases.
[14] D. Baltimore,et al. Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Fauci,et al. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.
[16] L. Kingsley,et al. Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. , 1993, Virology.
[17] T. Whiteside,et al. Effects of adoptive immunotherapy with autologous CD8+ T lymphocytes on immunologic parameters: lymphocyte subsets and cytotoxic activity. , 1993, Clinical immunology and immunopathology.
[18] H. Schuitemaker,et al. Virulent HIV strains? , 1993, AIDS.
[19] J. Sprent. Lifespans of naive, memory and effector lymphocytes. , 1993, Current opinion in immunology.
[20] J. Giorgi,et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. , 1993, Journal of immunology.
[21] X. Jin,et al. Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.
[22] K. Rosenthal,et al. The influence of lymphocyte counts and disease progression on circulating and inducible anti‐HIV-1 cytotoxic T‐cell activity in HIV‐1-infected subjects , 1992, AIDS.
[23] R. Weinstein,et al. In-Vitro Resistance to Zidovudine and Alpha-interferon in HIV-1 Isolates from Patients: Correlations with Treatment Duration and Response , 1992, Annals of Internal Medicine.
[24] R. Redfield,et al. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease , 1992, Journal of virology.
[25] Charles R. M. Bangham,et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.
[26] R. Koup,et al. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities , 1991, The Journal of experimental medicine.
[27] S. Buchbinder,et al. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. , 1991, The Journal of infectious diseases.
[28] B. Moss,et al. CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Margolick,et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.
[30] A. Régnault,et al. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence , 1990, European journal of immunology.
[31] B. Guy,et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins , 1989, Journal of virology.
[32] D. Tyler,et al. CELLULAR ANTI-GP120 CYTOLYTIC REACTIVITIES IN HIV-1 SEROPOSITIVE INDIVIDUALS , 1988, The Lancet.
[33] N. Letvin,et al. A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells , 1987, Nature.
[34] J. Phair,et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.
[35] B. Walker,et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.
[36] E. Podack,et al. Cytolytic cell functions , 1997 .
[37] Rolf M. Zinkernagel,et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.
[38] Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.
[39] R. Redfield,et al. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. , 1986, MMWR. Morbidity and mortality weekly report.
[40] Fazekas de St Groth. The evaluation of limiting dilution assays. , 1982, Journal of immunological methods.